Condition: Luteinised Follicular Cyst · Sponsor: IVI Madrid
The objective of this trial is to determine whether the use of letrozole during the luteal phase in oocyte donors diminishes the ovarian volume, as well as to evaluate its effect on the duration of the luteal phase, taking into account hormonal and biochemical markers. Two groups will be established with random allocation of patients and 1:1 proportionality, as follows: * Control group: No specific treatment. * Study group: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
This description comes directly from the study's public registry record.
Sergio Caballero, PhD · +34 91 180 29 00 · sergio.caballero@ivirma.com
Juan Antonio Garcia Velasco, PhD · +34 91 180 29 00 · juan.garcia.velasco@ivirma.com
Always discuss trial participation with your own doctor first.
| IVI-Madrid | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06244745